Detalles de la búsqueda
1.
Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial.
Value Health
; 27(2): 182-189, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37951539
2.
Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors.
J Oncol Pharm Pract
; 29(6): 1418-1427, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36131505
3.
Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
Oncologist
; 27(9): 790-798, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35781589
4.
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.
Future Oncol
; 18(20): 2499-2510, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608148
5.
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Oncologist
; 25(10): 867-877, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32490560
6.
Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Future Oncol
; 16(15): 1031-1041, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338548
7.
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Clin Lung Cancer
; 25(3): e145-e152.e3, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38114357
8.
Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
Cancer Med
; 12(5): 5494-5505, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36583557
9.
Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States.
Clin Lung Cancer
; 24(1): e39-e49, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36376172
10.
Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations.
JTO Clin Res Rep
; 4(10): 100558, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37744306
11.
Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
J Thorac Oncol
; 18(6): 744-754, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36738930
12.
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
J Thorac Oncol
; 18(12): 1743-1755, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37574132
13.
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Lung Cancer
; 179: 107186, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37075617
14.
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Lung Cancer
; 179: 107191, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37058788
15.
EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States.
JTO Clin Res Rep
; 3(3): 100285, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35199057
16.
Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes.
Curr Med Res Opin
; 38(8): 1341-1350, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35621011
17.
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
Curr Med Res Opin
; 38(9): 1587-1593, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35815801
18.
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
J Clin Med
; 12(1)2022 Dec 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36614913
19.
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
J Thorac Oncol
; 17(12): 1404-1414, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096442
20.
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
Eur J Cancer
; 170: 106-118, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35598358